A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Depatuxizumab mafodotin (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms Intellance1
- Sponsors AbbVie
- 16 Nov 2017 Planned number of patients changed from 720 to 640.
- 16 Nov 2017 Planned End Date changed from 17 Apr 2020 to 13 Feb 2021.
- 12 Jan 2017 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.